Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Equities researchers at HC Wainwright increased their FY2026 earnings estimates for shares of Oncolytics Biotech in a ...

Oncolytics Biotech's main asset, pelareorep, shows mixed results in trials, with no definitive efficacy signals and ongoing financial struggles threatening operations. The GOBLET trial in ...

Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08.

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights.